CanSino Biologics Inc. (CANSINOBIO) filed its Monthly Return for the period ended 30 June 2026, showing no movements in either authorised or issued share capital.

Authorised Share Capital • Total authorised capital remained at 247.04 million shares, split between 132.67 million H shares and 114.37 million A shares, each with a par value of RMB 1.

Issued Share Capital • Issued H shares: 132.67 million. • Issued A shares: 114.37 million. • No new shares were issued, repurchased or cancelled during the month. • Treasury share balance stayed at zero for both share classes.

Public Float • The company confirmed compliance with the 5 % minimum public-float requirement for its H-share class under HKEX Main Board Rule 13.32B.

Equity Incentive Plans • H-Share Core Management Option Scheme (adopted 23 Oct 2025): 860,000 options outstanding; no exercises in June. • A-Share Restricted Stock Incentive Scheme (adopted 23 Oct 2025): 2.05 million restricted shares remain available for future issuance; no grants, vesting or cancellations occurred in June.

Capital Structure Summary (as at 30 June 2026) • Total issued shares: 247.04 million. • Treasury shares: none. • Par value per share: RMB 1.

The filing, signed by Joint Company Secretary Jin Cui on 3 July 2026, indicates a period of capital stability with sufficient liquidity in the market for the Hong Kong-listed H shares.